Clinical Trials

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07325539 2026-04-13

LIGHT

55 enrolled

Nasopharyngeal Carcinoma

NCT07423078 2026-04-13

WOLF

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Phase 1 Recruiting

66 enrolled

Advanced Solid Tumors

NCT06457503 2026-04-06

TRANSPARENT

Phase 4 Recruiting

100 enrolled

Nasopharyngeal Neoplasms

NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06975293 2026-04-06

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas

107 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06281405 2026-04-03

TORCH-iTNT

192 enrolled

Locally Advanced Rectal Cancer

NCT06706219 2026-04-03

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

50 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07508761 2026-04-02

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

52 enrolled

Phase NA Not yet recruiting

Advanced Solid Tumor

NCT07500831 2026-03-30

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

43 enrolled

Carcinoma, Renal Cell

NCT06953323 2026-03-27

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

Advanced Solid Tumor

NCT07493980 2026-03-27

Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07480733 2026-03-25

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

480 enrolled

Phase 1 Active not recruiting

Advanced Malignant Solid Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Phase 1/2 Not yet recruiting

52 enrolled

Nasopharyngeal Carcinoma

NCT07481058 2026-03-20

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT05635643 2026-03-19

Study of CHS-114 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

87 enrolled

Squamous Cell Carcinoma of Head and Neck, Neoplasms

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

298 enrolled

Carcinoma, Renal Cell

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

146 enrolled

Muscle Invasive Bladder Cancer (MIBC)

NCT07469956 2026-03-13

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT05798845 2026-03-11

The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

124 enrolled

NSCLC

NCT04651127 2026-03-10

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Phase 1/2 Terminated

5 enrolled

Phase 1 Active not recruiting

Uterine Cervical Neoplasms

NCT05707910 2026-03-09

Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors

6 enrolled

Tumor-Agnostic

Neoplasms

NCT07209189 2026-03-09

(NeoScorch HN)

75 enrolled

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

NCT07457359 2026-03-09

NEOTRIO-2

18 enrolled

Triple Negative Breast Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Carcinoma, Renal Cell

NCT06208826 2026-03-03

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

268 enrolled

Head and Neck Neoplasms

NCT06719700 2026-03-03

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

47 enrolled

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT07277322 2026-03-02

Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases

24 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05888402 2026-02-27

InTRist

50 enrolled

Phase 2 Enrolling by invitation

Local Advanced Non-small Cell Lung Cancer

NCT05441475 2026-02-25

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

118 enrolled

Carcinoma, Hepatocellular

NCT07281716 2026-02-19

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

24 enrolled

Colorectal Neoplasms

NCT07410234 2026-02-13

Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy

110 enrolled

Breast Neoplasms

NCT04918186 2026-02-12

IPROC

60 enrolled

Ovarian Neoplasms

NCT07281976 2026-02-12

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

220 enrolled

Triple Negative Breast Neoplasms

NCT06592599 2026-02-10

Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)

24 enrolled

Nasopharyngeal Carcinoma

NCT07290621 2026-02-06

Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

30 enrolled

Phase 3 Not yet recruiting

Oropharyngeal Neoplasms

NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

440 enrolled

Cervical Cancer Metastatic

NCT07392736 2026-02-06

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

228 enrolled

Solid Tumor

NCT04418648 2026-02-04

Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy

Phase 2 Terminated

170 enrolled

Phase 1/2 Active not recruiting

Small Cell Lung Cancer Limited Stage

NCT05518045 2026-02-04

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

392 enrolled

Phase 1/2 Active not recruiting

Advanced Solid Tumor

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

500 enrolled

Solid Cancer

NCT07383818 2026-02-03

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

111 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06952621 2026-01-30

TD-NEOE3V3

390 enrolled

Phase 2/3 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT06984588 2026-01-30

A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

450 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07378306 2026-01-30

FACT-TN

80 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07376499 2026-01-29

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

31 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07371897 2026-01-28

SHINE

154 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07363330 2026-01-26

A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer

32 enrolled